杂合子丢失
生物
原发性中枢神经系统淋巴瘤
微卫星
免疫组织化学
抑癌基因
淋巴瘤
发病机制
抑制器
癌症研究
遗传学
等位基因
基因
病理
癌变
免疫学
医学
作者
Mitsutoshi Nakamura,Munehiro Kishi,Toshisuke Sakaki,Hiroyuki Hashimoto,Hiroyuki Nakase,Keiji Shimada,Eiwa Ishida,Noboru Konishi
出处
期刊:PubMed
日期:2003-02-15
卷期号:63 (4): 737-41
被引量:112
摘要
Deletions on the long arm of chromosome 6 (6q) are one of the most common chromosomal alterations in systemic high-grade non-Hodgkin's lymphomas. However, the locations of allelic deletions and their roles have not yet been reported in primary central nervous system lymphomas (PCNSLs), most of which are classed as non-Hodgkin's lymphoma. We thus performed fine loss of heterozygosity (LOH) mapping of 6q in 29 samples of surgically resected PCNSLs using 39 microsatellite markers to identify commonly deleted regions. LOH was found at 1 or more loci at 6q22-23 in 19 samples (66%); furthermore, 18 of these samples shared a deletion in the same small ( approximately 140 kb) region flanked by D6S1030 and D6S1690, a region in which the human R-PTP-kappa gene (PTPRK) is reported to be located. Reverse transcription-PCR analysis of the mRNA from 4 cases with 6q deletions confirmed loss of this gene, and loss of PTPRK expression was observed in 76% (22 of 29) of tumors with immunohistochemistry. In addition, LOH on 6q22-q23 significantly correlated to shorter patient survival (12.8 +/- 4.3 versus 23.4 +/- 3.5 months; P < 0.0001). Our results suggest that a 140-kb deletion located at 6q22-23 may contain the putative tumor suppressor, PTPRK, that appears to be relevant to the pathogenesis and prognosis of PCNSLs.
科研通智能强力驱动
Strongly Powered by AbleSci AI